TLR4 and mucopolysaccharidosis: Alternatively, infliximab, with its tumor necrosis factor (TNF)α-binding properties and effect on the TLR4–TNFα axis, was injected in MPS animals, and therapeutic benefits were appreciated when combined with standard ERT [254].